BPC-157 + TB-500 Blend 5mg / 5mg

For research use only — not for human or veterinary use.

Analytical Verification (COA)

Each batch of BPC-157 / TB-500 Blend supplied by Grail Formula undergoes independent third-party laboratory verification to confirm compound identity, assay content, purity and microbiological safety.

Analytical testing for this batch was performed by Liquilabs s.r.o. (Czechia) using validated chromatographic and spectrometric techniques.

Batch: GF082025024

Key analytical results include:

• BPC-157 Assay Content: 6.17 mg
• TB-500 (Thymosin Beta-4) Assay Content: 6.39 mg
• Bacterial Endotoxins: below 0.001 EU per mg
• Total Aerobic Microbial Count: not detected
• Total Yeast and Mold Count: not detected

Independent heavy metal screening confirmed no detectable levels of arsenic, cadmium, cobalt, lead, nickel, mercury or vanadium.

These analytical procedures ensure traceability, purity verification and laboratory-grade compound consistency.

Product Overview

The BPC-157 / TB-500 blend is a dual-peptide research preparation combining two synthetic peptides commonly studied in controlled laboratory environments investigating peptide-mediated cellular signalling pathways.

The formulation contains both BPC-157 and TB-500 within a single lyophilized preparation designed for experimental peptide interaction research and biochemical signalling studies.

This preparation contains a combined 10 mg of high purity lyophilized peptide material supplied in a sealed research vial. The lyophilization process preserves molecular stability and allows researchers to reconstitute the peptides for controlled in vitro experimentation.

Because of the defined peptide sequences and verified analytical profile, peptide combinations such as BPC-157 and TB-500 are frequently referenced in experimental models exploring peptide signalling and intracellular regulatory pathways.

Compound Overview

BPC-157 is a synthetic peptide derived from a biologically active protein fragment originally studied within gastric peptide research.

TB-500 represents a synthetic form of the active region of thymosin beta-4, a protein involved in cellular structural organisation and intracellular signalling mechanisms.

Within biochemical research environments, both peptides are investigated for their interactions with cellular signalling networks, cytoskeletal regulatory systems and molecular biochemical pathways.

The combination of these peptides within a single preparation allows researchers to study comparative peptide behaviour and signalling pathway interaction dynamics.

Historical Background and Scientific Context

Scientific interest in synthetic peptides expanded rapidly during the late twentieth century as advances in peptide synthesis enabled researchers to replicate biologically active fragments of larger proteins.

During the 1990s and early 2000s, laboratory investigations began focusing on peptide fragments capable of interacting with cellular signalling systems and regulatory biochemical pathways.

Both BPC-157 and thymosin-derived peptides have since been referenced in experimental biochemical research exploring peptide-mediated regulatory mechanisms.

Modern laboratory studies frequently investigate combinations of experimental peptides to analyse signalling pathway interactions and comparative molecular behaviour.

Mechanistic Focus in Research

Within experimental laboratory environments, the BPC-157 / TB-500 blend is studied in relation to peptide-mediated signalling pathways and molecular regulatory systems.

Research investigations commonly explore the peptides in experimental models examining:

• Peptide-receptor interaction mechanisms
• Cellular signalling pathway dynamics
• Cytoskeletal regulatory systems
• Intracellular signalling network modelling
• Comparative peptide interaction studies
• Molecular signalling cascade analysis
• Peptide-mediated biochemical processes

These experimental models allow scientists to investigate molecular regulatory mechanisms influencing cellular signalling behaviour and biochemical pathway interactions.

Research Applications

In controlled research environments, the BPC-157 / TB-500 blend may be utilised in experimental models designed to explore peptide signalling systems and intracellular regulatory pathways.

Examples of research applications include:

• Peptide signalling pathway investigation
• Comparative peptide interaction research
• Cell signalling analysis
• Molecular regulatory pathway studies
• Intracellular signalling network modelling
• Experimental biochemical peptide research
• Controlled in vitro peptide interaction studies

Grail Formula Quality

Every Grail Formula research compound is produced under strict quality control procedures designed to support reliable laboratory experimentation.

Each batch undergoes independent analytical testing to verify:

• Compound identity
• Assay accuracy
• Purity confirmation
• Microbial safety
• Endotoxin levels
• Heavy metal screening
• Full batch traceability

All testing is performed by independent laboratories to ensure transparent verification and reproducible research material.

Research Use Limitation

• Used solely for in vitro experiments
• Not permitted for clinical trials involving humans
• Not permitted for human or veterinary administration
• Not permitted for investigational human use

• Independently analysed by Liquilabs s.r.o. Czechia
• BPC-157 assay content verified at 6.17 mg
• TB-500 assay content verified at 6.39 mg
• Endotoxin level below 0.001 EU/mg
• No detectable microbial contamination
• No detectable heavy metals
• Dual-peptide research blend for regenerative studies
• For research use only – not for human or veterinary use

For laboratory research only. Not intended for human consumption, injection, or cosmetic use.

This product is for research purposes only. Not for human use or diagnostic/therapeutic applications. Keep out of reach of children.